What type of study is this?

This is a Validation Study study.

What question did this study set out to answer?

This research evaluates the safety and efficacy of gene therapy in improving hemolysis and monitoring clonal hematopoiesis in transfusion-dependent β-thalassemia patients.

December 8, 2025BloodOpen Access

Evaluating the efficacy and safety of gene therapy in transfusion-dependent β-thalassemia: A focus on hemolysis improvement and clonal hematopoiesis monitoring

View Full Paper

Ask AI

Bookmark

Authors

FBFlorence Beckerich AHAnoosha Habibi

Discussion

Member takes

Overview

Observational data shows gene therapy improves hemolysis in transfusion-dependent β-thalassemia, suggesting monitoring clonal hematopoiesis is crucial.

Key Points

This research evaluates the safety and efficacy of gene therapy in improving hemolysis and monitoring clonal hematopoiesis in transfusion-dependent β-thalassemia patients.
Real-world data analysis of a transfusion-dependent β-thalassemia patient treated with gene therapy.
Utilization of high-throughput panel for genes linked to clonal hematopoiesis and myeloid malignancies.
Monitoring of hemolysis biomarkers and gene editing rate post-treatment.
Patient achieved a significant reduction in hemolysis, with plasma heme decreasing by 98.5% post-gene therapy.
Sustained increase in edited alleles over 16 weeks, reflecting effective clonal editing.
Stable low frequency of a DNMT3A mutation observed, indicating no adverse clonal expansion.

Cite This Study

Beckerich et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236dddc https://doi.org/10.1182/blood-2025-2914

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Evaluating the efficacy and safety of gene therapy in transfusion-dependent β-thalassemia: A focus on hemolysis improvement and clonal hematopoiesis monitoring

View Full Paper

Ask AI

Bookmark

Authors

FBFlorence Beckerich AHAnoosha Habibi

Discussion

Member takes

Overview

Observational data shows gene therapy improves hemolysis in transfusion-dependent β-thalassemia, suggesting monitoring clonal hematopoiesis is crucial.

Key Points

This research evaluates the safety and efficacy of gene therapy in improving hemolysis and monitoring clonal hematopoiesis in transfusion-dependent β-thalassemia patients.
Real-world data analysis of a transfusion-dependent β-thalassemia patient treated with gene therapy.
Utilization of high-throughput panel for genes linked to clonal hematopoiesis and myeloid malignancies.
Monitoring of hemolysis biomarkers and gene editing rate post-treatment.
Patient achieved a significant reduction in hemolysis, with plasma heme decreasing by 98.5% post-gene therapy.
Sustained increase in edited alleles over 16 weeks, reflecting effective clonal editing.
Stable low frequency of a DNMT3A mutation observed, indicating no adverse clonal expansion.

Cite This Study

Beckerich et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236dddc https://doi.org/10.1182/blood-2025-2914

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark